Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Boehringer Ingelheim

Clinicaltrial registered9 Nov 2026

Boehringer Ingelheim

9 Nov 2026: Trial registered · A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
9 Nov 2026
Title
A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation
Conditions
Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Countries
United States, Australia, Japan, South Korea, Spain
Country
United States
Reference
NCT07926334
Location
United States, Australia, Japan
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Boehringer Ingelheim

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Boehringer Ingelheim in our registers.

More from United States

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.